Hoechst Pharmaceuticals of Canada v. Gilbert and Company

Hoechst Pharmaceuticals of Canada v. Gilbert and Company

Because claim 1 of each patent was overbroad — claiming an effectively infinite genus of sulfonyl ureas — it was invalid; under the Patent Act and applicable precedent a product claim to tolbutamide that is limited to 'whenever obtained according to claim 1' depends on a valid process claim and therefore fails when that foundational process claim is invalid; accordingly the patents could not support infringement and the appeal is dismissed.

Citation
[1966] SCR 189
Parties
Plaintiff/appellant: Hoechst Pharmaceuticals Of Canada Limited; Plaintiff/appellant: Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius & Bruning; Defendant/respondent: Gilbert & Company; Defendant/respondent: Gilbert Surgical Supply Co. Limited; Defendant/respondent: Jules R. Gilbert Limited
Court
Supreme Court of Canada
Jurisdiction
Canada
Judgment Date
14 December 1965
Procedural Posture
Patent Infringement (product by Process) / Appeal to Supreme Court of Canada From Judgment of the Exchequer Court of Canada; Final Decision on Appeal
Outcome
Appeal dismissed
Legal Topics
Patent Validity, Overbroad Claims, Process Claims, Product by Process Claims, Utility
Source Language
English
Intellectual Property Patent Law Patent Validity Overbroad Claims Process Claims Product by Process Claims Utility

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Legal principles 3 Authorities cited 7 Party arguments 2
Sign in to unlock

Parties

Hoechst Pharmaceuticals Of Canada Limited

Plaintiff/appellant

Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius & Bruning

Plaintiff/appellant

Gilbert & Company

Defendant/respondent

Gilbert Surgical Supply Co. Limited

Defendant/respondent

Jules R. Gilbert Limited

Defendant/respondent

Procedural Posture

Patent Infringement (product by Process) / Appeal to Supreme Court of Canada From Judgment of the Exchequer Court of Canada; Final Decision on Appeal

Legal Issues

  1. 1 Whether process claims (claim 1) were invalid for being overbroad and claiming a genus of chemically conceivable sulfonyl ureas
  2. 2 Whether a product claim to tolbutamide that is expressed as 'whenever obtained according to claim 1' can stand if the foundational process claim is invalid under the Patent Act
  3. 3 Whether unexpected utility (hypoglycemic activity) sufficed to render the claimed substances patentable given the breadth of the process claims

Ratio Decidendi

Because claim 1 of each patent was overbroad — claiming an effectively infinite genus of sulfonyl ureas — it was invalid; under the Patent Act and applicable precedent a product claim to tolbutamide that is limited to 'whenever obtained according to claim 1' depends on a valid process claim and therefore fails when that foundational process claim is invalid; accordingly the patents could not support infringement and the appeal is dismissed.

Court Disposition

Appeal dismissed

Orders

  • Appeal dismissed with costs